Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prenatal treatment of spinal muscular atrophy.

Servais L., (2025), Mol Ther

X-linked myotubular myopathy: an untreated treatable disease.

Martin C. and Servais L., (2025), Expert Opin Biol Ther, 1 - 16

Spinal muscular atrophy in the UK: the human toll of slow decisions.

Servais L. et al, (2025), Lancet, 405, 619 - 620

Wearable sensors in paediatric neurology.

González Barral C. and Servais L., (2025), Dev Med Child Neurol

Treatment strategies for patients with spinal muscular atrophy.

De Waele L. and Servais L., (2024), Expert Rev Neurother, 1 - 3

Treatments for RYR1-related disorders.

Raga S. et al, (2024), Cochrane Database Syst Rev, 12

Gene therapy for spinal muscular atrophy: timing is key.

Servais L., (2024), Lancet Reg Health Eur, 47

Spinal muscular atrophy in Brazil: from individual treatment to global management.

Servais L. and Moreno CAM., (2024), J Pediatr (Rio J)

Newborn screening programs for spinal muscular atrophy worldwide in 2023.

Vrščaj E. et al, (2024), J Neuromuscul Dis, 11, 1180 - 1189

Why should a 5q spinal muscular atrophy neonatal screening program be started?

Becker MM. et al, (2024), Arquivos de neuro-psiquiatria, 82, 1 - 9

Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.

Servais L. et al, (2024), International journal of molecular sciences, 25

Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.

Mackels L. et al, (2024), International journal of molecular sciences, 25

Load More